Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSP191 Conditioning for HCT in MDS or AML
NCT04429191Phase 1Completed
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of briquilimab in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Jasper Therapeutics, Inc. Primary endpoints: Number of subjects experiencing adverse events and serious adverse events at 1 year, Number of dose limiting toxicities at 1 year and 1 more. Started Jul 2020; status: completed.
02
Drugs
briquilimab
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04429191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429191.